291 related articles for article (PubMed ID: 24993072)
1. Metastatic breast cancer subtypes and central nervous system metastases.
Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
[TBL] [Abstract][Full Text] [Related]
2. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer subtypes and outcomes of central nervous system metastases.
Arslan UY; Oksuzoglu B; Aksoy S; Harputluoglu H; Turker I; Ozisik Y; Dizdar O; Altundag K; Alkis N; Zengin N
Breast; 2011 Dec; 20(6):562-7. PubMed ID: 21871802
[TBL] [Abstract][Full Text] [Related]
7. Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases.
Dyer MA; Kelly PJ; Chen YH; Pinnell NE; Claus EB; Lee EQ; Weiss SE; Arvold ND; Lin NU; Alexander BM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e479-86. PubMed ID: 22704705
[TBL] [Abstract][Full Text] [Related]
8. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
[TBL] [Abstract][Full Text] [Related]
11. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer brain metastases - A 12 year review of treatment outcomes.
De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
Gonçalves A; Deblock M; Esterni B; Tarpin C; Bertucci F; Gilabert M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G; Extra JM; Viens P
Anticancer Drugs; 2009 Nov; 20(10):946-52. PubMed ID: 19741502
[TBL] [Abstract][Full Text] [Related]
15. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
17. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
Gonzalez-Angulo AM; Cristofanilli M; Strom EA; Buzdar AU; Kau SW; Broglio KR; Smith TL; Hortobagyi GN
Cancer; 2004 Oct; 101(8):1760-6. PubMed ID: 15386311
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
20. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
